Compile Data Set for Download or QSAR
Report error Found 44 Enz. Inhib. hit(s) with all data for entry = 12555
TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708839(US20240425513, Example 20)
Affinity DataIC50: 1nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708863(US20240425513, Example 44)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708845(US20240425513, Example 26)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708846(US20240425513, Example 27)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708843(US20240425513, Example 24)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708844(US20240425513, Example 25)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708841(US20240425513, Example 22)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708840(US20240425513, Example 21)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708853(US20240425513, Example 34)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708854(US20240425513, Example 35)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708851(US20240425513, Example 32)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708852(US20240425513, Example 33)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708847(US20240425513, Example 28)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708848(US20240425513, Example 29)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708862(US20240425513, Example 43)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708859(US20240425513, Example 40)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708860(US20240425513, Example 41)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708857(US20240425513, Example 38)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708858(US20240425513, Example 39)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708855(US20240425513, Example 36)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708856(US20240425513, Example 37)
Affinity DataIC50: 50nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708837(US20240425513, Example 18)
Affinity DataIC50: 275nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708833(US20240425513, Example 14)
Affinity DataIC50: 275nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708834(US20240425513, Example 15)
Affinity DataIC50: 275nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708842(US20240425513, Example 23)
Affinity DataIC50: 275nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708822(US20240425513, Example 3)
Affinity DataIC50: 275nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708849(US20240425513, Example 30)
Affinity DataIC50: 275nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708850(US20240425513, Example 31)
Affinity DataIC50: 275nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708861(US20240425513, Example 42)
Affinity DataIC50: 275nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708829(US20240425513, Example 10)
Affinity DataIC50: 275nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708828(US20240425513, Example 9)
Affinity DataIC50: 275nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708825(US20240425513, Example 6)
Affinity DataIC50: 275nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708823(US20240425513, Example 4)
Affinity DataIC50: 275nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708824(US20240425513, Example 5)
Affinity DataIC50: 275nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708838(US20240425513, Example 19)
Affinity DataIC50: 750nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708832(US20240425513, Example 13)
Affinity DataIC50: 750nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708827(US20240425513, Example 8)
Affinity DataIC50: 750nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708821(US20240425513, Example 2)
Affinity DataIC50: 1.00E+3nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708835(US20240425513, Example 16)
Affinity DataIC50: 1.00E+3nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708836(US20240425513, Example 17)
Affinity DataIC50: 1.00E+3nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708820(US20240425513, Example 1)
Affinity DataIC50: 1.00E+3nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708831(US20240425513, Example 12)
Affinity DataIC50: 1.00E+3nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708830(US20240425513, Example 11)
Affinity DataIC50: 1.00E+3nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetUbiquitin carboxyl-terminal hydrolase 28(Human)
Carmot Therapeutics

US Patent
LigandPNGBDBM708826(US20240425513, Example 7)
Affinity DataIC50: 1.00E+3nMAssay Description:Each assay was performed in a final volume of 8 μl in assay buffer containing 10 mM HEPES pH 7.3 ((1 M, pH 7.3 solution, (VWR J848), 100 mM NaCl (5 M...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent